

## DIASORIN ANNOUNCES CLEARANCE OF THE LIAISON XL SYSTEM BY THE FDA FOR COMMERCIALIZATION IN THE US MARKET.

*Saluggia, January 26<sup>th</sup> 2011-* DiaSorin, a worldwide leader in the in vitro diagnostic market, has received today clearance from the FDA, the US Regulatory body, for the commercialization in the US of the LIAISON XL system. The plan foresees to start commercial availability of the instrument by the end of the second quarter 2011 to support certain large laboratories in the US that are currently faced with increasing volumes, especially of VIT D testing.

The LIAISON XL has been developed by DiaSorin to maximize the through-put of its existing LIAISON products to allow the Company to better serve a segment of the market (i.e. large commercial laboratories) which is rapidly expanding as a result of lab consolidation worldwide. Products like DiaSorin VIT D Total test will benefit from the increased capacity provided by the LIAISON XL and the through-put is expected to increase up to 180 tests per hour, doubling the one reached today with the LIAISON platform or similar platforms provided by competitors.

The LIAISON XL has been launched in Europe in December 2010 along with the new line of Hepatitis and HIV products which were all CE marked in 2010.

Mr. Carlo Rosa, DiaSorin CEO, commented the news saying: "Strategically the US market represents a primary focus for DiaSorin and it has been growing in the past few years representing now almost 35% of the Company revenues. The LIAISON XL is key to continue the successful growth of DiaSorin, especially in those markets like the US where laboratory consolidation has been going on for years and very large commercial labs dominate the market. Moreover, products like our VIT D test will significantly benefit from the capacity offered by this new platform and we will be able to provide our customers with a unique solution to support them in facing increased volumes of this test"



**About DiaSorin**

DiaSorin S.p.A., an international player in the market for in vitro diagnostics, develops, produces and markets reagent kits for clinical laboratory diagnostics. The DiaSorin Group is comprised of 23 companies based in Europe, North, Central and South America, Africa and Asia. It has about 1,500 employees, including more than 110 research and development specialists, and operates six manufacturing and research facilities in Saluggia (Vercelli, Italy), Dietzenbach (Germany), Stillwater (USA), Dublin (Ireland), Dartford (UK) and Kyalami (SA). The last two were part of the Murex business operations, recently acquired from the Abbott Group. Thanks to its direct sales organization and an international network of over 80 independent distributors, the Group is present in more than 60 countries, offering a broad array of high quality products that includes comprehensive lines for each of the clinical segments in which the Group operates: infectious and viral diseases, management of bone and calcium related diseases, thyroid pathologies, oncology and fertility testing.

For additional information, please visit our website: [www.DiaSorin.com](http://www.DiaSorin.com)

---

Contacts:

**Investor Relations Director**

Laura Villa

**DiaSorin S.p.A.**

[laura.villa@DiaSorin.it](mailto:laura.villa@DiaSorin.it)

+39 0296474567

+39 3481511542

**Press Office**

Carolina Mailander

[c.mailander@mailander.it](mailto:c.mailander@mailander.it)

+39 3356555651

Bruno Caprioli

[caprioli@mailander.it](mailto:caprioli@mailander.it)